Daniel W. Muehl, See Remarks at Clovis Oncology, Inc. (CLVS), sold 456 shares at $6.29 ($3K) on 2021-03-01, disclosed to the SEC on 2021-03-03.
Seasonal sale ($3k) by See Remarks — this insider has traded CLVS in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.29 | 207 | $1K | 45.4% |
| 2 | $6.29 | 249 | $2K | 54.6% |
| Total | $6.29 avg | 456 | $3K | 100% |
| Filing → |
| CLVS | SELL | 2022-08-03 | $7K | — | Filing → |
| CLVS | SELL | 2022-06-03 | $1K | — | Filing → |
| CLVS | SELL | 2022-05-03 | $9K | — | Filing → |